Sex differences in in vivo biomarkers of neurodegenerative dementia

作者：Elijah E Mak, Kejal Kantarci, Zoe Arvanitakis · 发表于：Frontiers in Dementia · 年份：2025 · DOI：10.3389/frdem.2025.1706177 · 被引用次数：6 · 研究领域：Alzheimer's disease research and treatments、Dementia and Cognitive Impairment Research、Amyotrophic Lateral Sclerosis Research

Background Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) are two of the most common neurodegenerative diseases in older adults, and both show well-documented sex-specific differences in terms of clinical presentation, prevalence, and progression trajectories. However, the underlying neurobiological substrates that underpin these differences are poorly understood. In vivo biomarkers are well-suited to yield insights into how biological sex may shape disease pathophysiology in AD and DLB, and thus inform future research and precision medicine. The objective of this review is to synthesize recent evidence on sex differences related to biomarkers of AD and DLB. Methods We conducted a literature search of PubMed for studies published between January 2000 and May 2025 examining sex differences in neuroimaging and biofluid markers of mild cognitive impairment (MCI), AD, and/or DLB. Eligible studies were required to include sex-stratified or sex-interaction analyses in human participants with clinically defined MCI (due to AD or DLB), AD, or DLB. Results Of a total of 261 articles imported for screening, 63 met inclusion criteria, comprising 50 cross-sectional and 13 longitudinal investigations across biofluid markers ( n = 18) studies, structural imaging ( n = 18), functional imaging ( n = 16), and molecular imaging ( n = 11) studies. Women demonstrated initial cortical structural and metabolic advantages followed by accelerated decline. In MCI and AD, women were gene...